Pharma BD Deal Intelligence
Viatris to buy two eye drug developers Oyster Point and Famy in deals worth up to $750M to enter ophthalmology with Tyrvaya dry eye spray
SEC 8-K/A filing documenting Viatris acquisition of Oyster Point Pharma at $11 per share plus contingent value right of up to $2 per share
2026 post-close status: Viatris Eye Care Division retained (not divested); Tyrvaya ~10-12% dry-eye share; Ryzumvi launched 2024; MR-141 presbyopia PDUFA Oct…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Viatris Inc. acquired Oyster Point Pharma, Inc. (Nasdaq: OYST), an ophthalmology-focused biopharmaceutical company, under a merger agreement announced November 7, 2022 and completed January 3, 2023 via tender offer. Viatris paid $11.00 per share in cash (~$424M equity value; ~$298.8M net) plus one non-tradeable contingent value right (CVR) per share worth up to an additional $2.00 per share tied to Oyster Point's full-year 2022 Tyrvaya performance. The lead asset, Tyrvaya (varenicline solution) nasal spray, was the first FDA-approved nasal spray for dry eye disease (approved 2021), acting via the trigeminal parasympathetic pathway to stimulate natural tear production. Acquired concurrently with Famy Life Sciences, the transaction established Viatris's new Eye Care Division and its entry into branded specialty ophthalmology. As of 2026 the franchise remains core to Viatris's specialty-medicines strategy: Tyrvaya holds roughly 10-12% dry-eye market share, Ryzumvi (phentolamine, pupil-dilation reversal) launched in 2024, and pipeline asset MR-141 (presbyopia eye drop) carries an FDA PDUFA date of October 17, 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Viatris / Oyster Point Pharma, Inc. (this deal) | 2022 | $299M | 58 |
| Johnson & Johnson / Abbott Medical Optics | 2003 | $4.3B | 70 |
| Johnson & Johnson / Abbott Laboratories (Abbott Medical Optics) | 2016 | $4.3B | 66 |
| Merck & Co. Inc. / EyeBio Ltd. | 2024 | $3.0B | 61 |
| Teva Pharmaceutical Industries Ltd. / Samsung Bioepis Co., Ltd. | 2026 | — | 51 |
| EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license) | 2000 | $32M | 47 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
← Browse all deals · How we score deals
More: 2022 deals · Ophthalmology deals